TVTX Options (TVTX20260220P25) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About TVTX20260220P25

Underlying

Travere Therapeutics, Inc.

Industry

Pharmaceutical

Introduction

Travere Therapeutics, Inc., incorporated as Desert Gatewayinc on February 8, 2008, is registered in Oklahoma. Retrophin is a developing biopharmaceutical company dedicated to the development, acquisition and commercialization of therapeutic therapies for serious, catastrophic and rare diseases. In the United States, Retrophin is working on the development of SyntocinonTM Nasal Spray to aid postpartum milk secretion and can be used to treat schizophrenia and autism. Syntocinon Nasal Spray is currently marketed by Novartis and Sigma-Tau in Europe and other countries to help pregnant women with postpartum milk secretion. In addition, Retrophin is developing RE-034, a synthetic hormone analog consisting of 24 of the 39 amino acids contained in ACTH, for the treatment of infantile spasms and nephrotic syndrome. Retrophin is also working on re-024, a new small molecule for the potential treatment of pantothenate neurodegenerative disease. At the same time, the company is developing sparsentan, formerly known as re-021, a dual-acting angiotensin receptor and endothelin receptor for the treatment of focal segmental glomerulosclerosis. Retrophin also has several additional programs in clinical development, including re-001, for the treatment of Duchenne muscular dystrophy.